Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27641 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Lily J Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of General Surgery, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Surgical Wound Infection, Metronidazole, Antibiotic Prophylaxis. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Preoperative antibiotic options for pancreaticoduodenectomy (PD) include cefoxitin (CX), piperacillin‐tazobactam (PT), or combined cefazolin and metronidazole (CM). Recent studies suggest the superiority of PT over CX, but evidence for CM is unclear.
Objective
To explore the impact of preoperative antibiotic selection (CM vs. PT and CX vs. PT) on the development of surgical site infections (SSI).
Methods
Consecutive adult patients at one institution who underwent PD from November 2017 to December 2021 and received either CM, PT, or CX preoperatively, were included. The primary outcome was SSI. Secondary outcomes included postoperative infections and clinically significant postoperative pancreatic fistula (POPF). Logistic regression models were used.
Results
Among 127 patients included in the study, PT, CM, and CX were administered in 46 (36.2%), 44 (34.6%), and 37 (29.4%) patients, respectively. There were 32 (27.1%) SSI, 20 (36.1%) infections, and 21 (22.9%) POPF events. PT use was associated with reduced risk of SSI compared to CX (OR: 0.32, 95% CI: 0.11−0.89, p = 0.03), but there was no difference as compared to CM (OR: 0.75, 95% CI: 0.27−2.13, p = 0.59). There were no differences in secondary outcomes.
Conclusion
PT reduced SSI rates compared to CX but was no different to CM among patients undergoing PD at our center.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of General Surgery, McMaster University, Hamilton, Ontario, Canada.
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada.
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
- NYU Langone Health, New York University, New York, New York, USA.
- Department of Medicine, Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada.
Zitieren
APA
Park, L. J., D'Souza, D., Kazi, T., Rodriguez, F., Griffiths, C., McKechnie, T., Mertz, D., & Serrano, P. E. (2024). Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27641
Vancouver
Park LJ, D'Souza D, Kazi T, Rodriguez F, Griffiths C, McKechnie T, et al. Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27641
BibTeX
@article{Park2024,
author = {Park, Lily J and D'Souza, Daniel and Kazi, Tania and Rodriguez, Felipe and Griffiths, Christopher and McKechnie, Tyler and Mertz, Dominik and Serrano, Pablo E},
title = {Comparing cefazolin/metronidazole, piperacillin‐tazobactam, or cefoxitin as surgical antibiotic prophylaxis in patients undergoing pancreaticoduodenectomy: A retrospective cohort study},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27641}
}
EUVIMED